Alzheimer's disease drug development pipeline: 2017
Tóm tắt
There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies.
We assessed the agents in the AD pipeline as documented in
There are 105 agents in the AD treatment development pipeline, of which 25 agents are in 29 trials in phase I, 52 agents are in 68 trials in phase II, and 28 agents are in 42 trials in phase III. Seventy percent of drugs in the AD pipeline are disease‐modifying therapies (DMTs). Fourteen percent are symptomatic cognitive enhancers, and 13% are symptomatic agents addressing neuropsychiatric and behavioral changes (2% have undisclosed mechanisms). Most trials are sponsored by the biopharmaceutical industry. Trials include patients with preclinical AD (cognitively normal with biomarker evidence of AD), prodromal AD (mild cognitive symptoms and biomarker evidence of AD), and AD dementia. Biomarkers are included in many drug development programs particularly those for DMTs. Thirteen of 46 phase II DMT trials have amyloid imaging as an entry criterion, and 10 of 28 phase III trials incorporate amyloid imaging for diagnosis and entry. A large number of participants are needed for AD clinical trials; in total, 54,073 participants are required for trials spanning preclinical AD to AD dementia. When compared with the 2016 pipeline, there are eight new agents in phase I, 16 in phase II, and five in phase III.
The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. The trials include a wide range of clinical trial populations, many mechanisms of action, and require a substantial number of clinical trial participants. Biomarkers are increasingly used in patient identification and as outcome measures, particularly in trials of DMTs.
Từ khóa
Tài liệu tham khảo
Alzheimer's Association, 2015, Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars
Cummings J.L., 2016, Developing Therapeutics for Alzheimer's Disease, 459, 10.1016/B978-0-12-802173-6.00017-4
Cummings J., 2016, Alzheimer's drug development pipeline: 2016, Alzheimers Dement, 2, 222, 10.1016/j.trci.2016.07.001
Curry S., 2011, Principles and Practice of Pharmaceutical Medicine, 84
Kelley J., 2009, Principles of CNS Drug Development: From Test Tube to Patient
Norfleet E., 2009, Clinical Trials Handbook, 245
Tan S.B., 2009, Clinical Trials Handbook, 255
Viglietta V., 2017, Titration dosing of aducanumab: results of a 12‐month interim analysis from a randomized, double‐blind, placebo‐controlled phase 1b study (PRIME) in patients with prodromal or mild Alzheimer's disease (S7.003), Neurology, 88, 16
Jekunen A., 2014, Decision‐making in product portfolios of pharmaceutical research and development–managing streams of innovation in highly regulated markets, Drug Des Devel Ther, 8, 2009, 10.2147/DDDT.S68579
Babic T., 2016, Improving screen fail and recruitment rates in Alzheimer's disease clinical trials, J Clin Stud, 8, 38
Cummings J.L., 2016, Re‐engineering Alzheimer clinical trials: Global Alzheimer Platform Network, J Prev Alzheimers Dis, 3, 114
Hawkes N., 2017, Merck ends trial of potential Alzheimer's drug verubecestat, BMJ, 356
Le Couteur D.G., 2016, Solanezumab and the amyloid hypothesis for Alzheimer's disease, BMJ, 355
Refolo L.M., 2006, Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases, Curr Alzheimer Res, 3, 175, 10.2174/156720506777632853